Follow-up | Male | Female | OR [CI 95%], p value (univariate analysis) | OR [CI 95%], p value (multivariate analysis*) |
6 months | n=179 | n=683 | ||
Remission (%) | 33 (18.4) | 72 (10.5) | 0.52 [0.33 to 0.82], p=0.005 | 0.62 [0.34 to 1.15], p=0.13 |
EULAR response (%) | n=155 | n=624 | ||
Without response | 85 (54.8) | 297 (47.6) | 1 | 1 |
Moderate response | 39 (25.2) | 231 (37) | 1.70 [1.12 to 2.57], p=0.01 | 1.80 [1.08 to 3.00], p=0.02 |
Good response | 31 (20.0) | 96 (15.4) | 0.89 [0.55 to 1.42], p=0.62 | 1.13 [0.62 to 2.06], p=0.68 |
Good or moderate | 70 (45.2) | 327 (52.4) | 1.34 [0.94 to 1.90], p=0.11 | 1.50 [0.97 to 2.32], p=0.07 |
12 months | n=191 | n=722 | ||
Remission (%) | 35 (18.3) | 81 (11.2) | 0.56 [0.37 to 0.87], p=0.009 | 0.80 [0.42 to 1.53], p=0.51 |
EULAR response (%) | n=169 | n=661 | ||
Without response | 98 (58.0) | 375 (56.7) | 1 | 1 |
Moderate response | 41 (24.3) | 189 (28.6) | 1.20 [0.80 to 1.80], p=0.37 | 1.21 [0.72 to 2.04], p=0.46 |
Good response | 30 (17.7) | 97 (14.7) | 0.84 [0.53 to 1.35], p=0.48 | 0.85 [0.47 to 1.54], p=0.60 |
Good or moderate | 71 (42.0) | 286 (43.3) | 1.05 [0.75 to 1.48], p=0.77 | 0.81 [0.46 to 1.42], p=0.47 |
24 months | n=197 | n=741 | ||
Remission (%) | 39 (19.8) | 75 (10.1) | 0.46 [0.30 to 0.70], p<0.001 | 0.69 [0.37 to 1.28], p=0.24 |
EULAR response (%) | n=180 | n=685 | ||
Without response | 114 (63.3) | 449 (65.6) | 1 | 1 |
Moderate response | 31 (17.2) | 147 (21.5) | 1.20 [0.78 to 1.87], p=0.41 | 1.12 [0.65 to 1.90], p=0.69 |
Good response | 35 (19.4) | 89 (13.0) | 0.65 [0.42 to 1.00], p=0.052 | 0.77 [0.43 to 1.37], p=0.37 |
Good or moderate | 66 (36.7) | 236 (34.5) | 0.91 [0.65 to 1.28], p=0.58 | 0.85 [0.42 to 1.71], p=0.64 |
Treatment discontinuation for inefficacy was considered as a non-response/non-remission, and missing data (at 6, 12 and 24 months) were imputed using last observation carry forward.
*After adjustment on age, disease duration, RF or anti-CCP positivity, current DMARDs or previous tumour necrosis factor blockers and corticoids use, and rheumatoid arthritis activity.
EULAR, European League Against Rheumatism.